LAUSANNE, Switzerland, November 10 /PRNewswire/ --
- Gene Signal International, a Biotech Company Registered in Switzerland, Will Move its Headquarters to the EPFL, in Lausanne, - Gene Signal is Addressing Various Issues Related to Neovascularisation, - Gene Signal is Working on a Portfolio of Ophthalmologic Indications, With One Now in Phase III Trials - Gene Signal Will Present its Interim Results at the Annual Meeting of the American Academy of Ophtalmologist in Atlanta, USA, the Largest Scientific Convention in this Field
Gene Signal, a biotech company registered in Switzerland, is currently starting the Phase III study of GS-101, its most advanced therapeutic ophthalmic solution, for the prevention of corneal graft rejection.